IOncology

Editor’s Note : From November 6–9, 2025, the China Conference on Holistic and Integrative Oncology (CCHIO) was held in Kunming, bringing together leading oncology experts from across China and abroad.…

2025 CCHIO CACA–NCCN Summit Review** Editor’s Note: The 2025 China Conference on Holistic Integrative Oncology (CCHIO)—hosted by the China Anti-Cancer Association (CACA) and the Tengchong Scientist Forum Organizing Committee Office,…

Editor’s Note: On November 8, 2025, during the China Conference on Holistic and Integrative Oncology (CCHIO), the China Anti-Cancer Association (CACA) held a grand signing ceremony for Memoranda of Understanding…

Editor’s Note On November 8, 2025, the International Academician Forum of the China Conference on Holistic and Integrative Oncology (CCHIO) was held in Kunming with exceptional grandeur. The forum brought…

Editor’s Note: The 2025 China Conference on Holistic Integrative Oncology (CCHIO), jointly organized by the Chinese Anti-Cancer Association (CACA) and the Tengchong Scientist Forum Organizing Committee Office, and co-hosted by…

Editor’s Note On November 8, 2025, during the China Conference on Holistic and Integrative Oncology (CCHIO), the China Anti-Cancer Association (CACA) and the American Association for Cancer Research (AACR) jointly…

Editor's note: At the recently concluded 13th Federation of Asian Clinical Oncology (FACO 2025) Annual Meeting, Oncology Frontier, together with International Hepatology, interviewed Dr. Su Jiayong from the Affiliated Cancer…

Editor’s Note: China, Japan, South Korea and other East Asian countries share a high prevalence of hepatobiliary and pancreatic tumors, yet current treatment options still fall short of clinical needs.…

China, Japan, and other Asian countries represent the regions with the highest global incidence of gastric cancer. In China, most patients are still diagnosed at advanced stages, losing the opportunity for curative surgery. Effective systemic therapies are therefore critical to improving survival. In recent years, innovative therapies—particularly antibody–drug conjugates (ADCs)—have shown promising results. Among them, the HER2-targeted ADC trastuzumab deruxtecan (T-DXd) has achieved success in key clinical studies such as DESTINY-Gastric04, and is poised to reshape treatment paradigms starting from later-line settings. Asian investigators have played an important role in these practice-changing studies.